The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib
- Conditions
- Pulmonary Fibrosis
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 493
- Registration Number
- NCT06912659
A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT06791187
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
- Conditions
- Colorectal CarcinomaGastric CarcinomaPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT06882746
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
🇩🇪Technische Universität Dresden, Dresden, Germany
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Drug: Spevigo®
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT06886009
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
- Conditions
- Type 1 Interferonopathies
- Interventions
- Drug: BI 3000202_low doseDrug: BI 3000202_high dose
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT06878365
- Locations
- 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇫🇷HOP Gui de Chauliac, Montpellier, France
🇫🇷HOP Necker, Paris, France
The AIRTIVITY® Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
- Conditions
- Bronchiectasis
- Interventions
- Drug: Placebo matching BI 1291583
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1680
- Registration Number
- NCT06872892
- Locations
- 🇧🇬
Medical Center "Pulmovision", Sofia, Bulgaria
🇯🇵Matsue Medical Center, Shimane, Matsue, Japan
🇧🇬Medical Center Tara, Veliko Tarnovo, Bulgaria
A Study in Healthy Men to Test Whether Food Influences the Amount of BI 3731579 in the Blood
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT06861829
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
- Conditions
- Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
- Interventions
- Drug: Placebo matching nerandomilast
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 400
- Registration Number
- NCT06806592
- Locations
- 🇫🇷
HOP Sud, Rennes, France
🇫🇷HOP Civil, Strasbourg, France
🇫🇷HOP Rangueil, Toulouse, France
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT06806852
- Locations
- 🇺🇸
Norton Cancer Institute, Downtown, Louisville, Kentucky, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇦🇺Gosford Hospital, Gosford, New South Wales, Australia
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT06791122
- Locations
- 🇺🇸
North County Clinical Research, Oceanside, California, United States
🇺🇸CT Clinical Research, Cromwell, Connecticut, United States
🇺🇸Health Synergy Clinical Research, LLC, West Palm Beach, Florida, United States